Chengdu Suncadia Medicine Co., Ltd.
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 capsule
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT06715943
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, Tianjin, China
A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects
- Conditions
- Hemolytic Anemia
- Interventions
- Drug: HRS-5965 capsuleDrug: HRS-5965 capsule placebo
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06684041
- Locations
- 🇨🇳
Zhongnan hospital of Wuhan University, Wuhan, Hubei, China
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment
- Conditions
- Complement Mediated Primary or Secondary Glomerular Diseases
- Interventions
- Drug: HRS-5965 capsules
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06674915
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 capsule
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06593938
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers
- Conditions
- Complement Mediated Primary or Secondary Glomerular Diseases
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06567392
- Locations
- 🇨🇳
The First Affiliated Hospital Of Shandong First Medical University（Shandong Provincial Qianfoshan Hospital）, Jinan, Shandong, China
Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria，IgA Nephropathy
- Interventions
- Drug: HRS-5965 tablets；HRS-5965 capsules
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06490991
- Locations
- 🇨🇳
ZhongShan Hospital FuDan University, ShangHai, Shanghai, China
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 tabletsDrug: HRS-5965 Capsules
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06238544
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
- Conditions
- Primary IgA Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT06137768
- Locations
- 🇨🇳
Beijing University First Hospital, Beijing, Beijing, China
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 tablets
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT06051357
- Locations
- 🇨🇳
The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: HRS9950 tabletsDrug: HRS9950 placebo tablets
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05905458
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China